Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medmix AGMDMXF 68 EV-to-EBITDA is 7.91 as of Aug. 04, 2026, which is 26% below its 10-year median of 10.65. GuruFocus rates MDMXF with a GF Score™ of 68/100 and a GF Value™ of $17.95. The stock has 6 warning signs investors should review. Among 2,477 Industrial Products companies, Medmix AG ranks better than 74.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medmix AG's enterprise value is $713.8 Mil.
Medmix AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $90.2 Mil. Therefore, Medmix AG's EV-to-EBITDA for today is 7.91.
The historical rank and industry rank for Medmix AG's EV-to-EBITDA or its related term are showing as below:
MDMXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.97 Med: 10.65 Max: 36.3
Current: 7.99
During the past 8 years, the highest EV-to-EBITDA of Medmix AG was 36.30. The lowest was 6.97. And the median was 10.65.
MDMXF's EV-to-EBITDA is ranked better than 74.12% of 2477
companies
in the Industrial Products industry
Industry Median: 15.65
vs MDMXF: 7.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medmix AG's share price for today is $17.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medmix AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.188.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medmix AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Medmix AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG EV-to-EBITDA vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medmix AG's EV-to-EBITDA falls into.
Medmix AG's current Enterprise Value is $713.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medmix AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $90.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medmix AG (MDMXF) has a EV-to-EBITDA of 7.91 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medmix AG. This is 26% below median its historical median of 10.65. Over the past decade, Medmix AG's EV-to-EBITDA has ranged from 6.97 to 36.30. According to the industry distribution chart, Medmix AG ranks #641 out of 2477 companies in the Industrial Products industry, placing it in the top 25.9%.
Is Medmix AG's EV-to-EBITDA too high?
Medmix AG's current EV-to-EBITDA of 7.91 is 26% below median its 10-year median of 10.65. Over the past 10 years, this metric has ranged from a low of 6.97 to a high of 36.30. The Industrial Products industry median EV-to-EBITDA is 15.65. Medmix AG's value of 7.91 is 49.5% below this industry median. Based on the distribution chart, Medmix AG ranks #641 out of 2477 companies in the Industrial Products industry, which is above the industry midpoint. Overall, Medmix AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's EV-to-EBITDA compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #641 out of 2477 companies for EV-to-EBITDA. This puts Medmix AG in the upper half of its industry. The industry median EV-to-EBITDA is 15.65. Medmix AG's value of 7.91 is 49.5% below this benchmark. Historically, Medmix AG's own EV-to-EBITDA has ranged from 6.97 to 36.30 over the past decade. While the company's 10-year median is 10.65 vs. the industry median of 15.65, Medmix AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for an Industrial Products company?
The median EV-to-EBITDA among Industrial Products companies is 15.65, based on 2,477 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current EV-to-EBITDA of 7.91 is 49.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medmix AG. For the Industrial Products industry, the median EV-to-EBITDA is 15.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current EV-to-EBITDA is 7.91, which is 26% below median its own 10-year median of 10.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current EV-to-EBITDA of 7.91. The stock's GF Value™ is $17.95, compared to a current price of $17.40 — trading 3.1% below its estimated fair value. The current EV-to-EBITDA is 7.91, which is 26% below median its 10-year median of 10.65 and 49.5% below the Industrial Products industry median of 15.65. Medmix AG's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medmix AG (MDMXF), the current EV-to-EBITDA is 7.91 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (MDMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of $17.40 is trading 3.1% below its estimated GF Value™ of $17.95.
Key valuation signals for MDMXF:
EV-to-EBITDA: 7.91 (26% below median its 10-year median of 10.65)
GF Value™: $17.95 vs. price of $17.40 (3.1% below fair value)
Industry Position: 49.5% below the Industrial Products median (#641 of 2477)
No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
68GF Score
Get the complete analysis for MDMXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDMXF has been successfully added to your 
